About
Annovis Bio Inc (NYSE:ANVS) — investor relations, events, news, and company updates on 6ix.
Latest News
Today
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
Apr 10 2026
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
Apr 9 2026
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
Apr 2 2026
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
Mar 31 2026
Annovis Publishes Historical Review of Buntanetap in The Scientist
Financials
Revenue
$0
Market Cap
$64.65 M
EPS
-1.40
